Shisong Jiang is appointed to the newly created role of Senior Industrial Fellow in the Department of Oncology at the University of Oxford
Oxford, UK – 9th November 2020 – FOR IMMEDIATE RELEASE
Oxford 9th November 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on the development of a new generation of cancer vaccines, announced today that the founder of the company, Dr. Shisong Jiang, has been appointed to the newly created role of Senior Industrial Fellow in the University Department of Oncology.
This role has been created in line with the new strategy for the Department of Oncology to focus more on translational medicine and on building relationships with industry. Shisong Jiang invented the concept of recombinant overlapping peptides (ROPs) as the basis for a new generation of vaccines and diagnostics for both cancer and infectious diseases and is well placed to take this new role. He founded both Oxford Vacmedix, using the ROP technology platform to develop cancer vaccines, and also Changzhou Biotech (CBI), focused on diagnostic applications of the technology. Shisong’s current research is funded by an industrial grant made jointly between OVM and CBI, who hold the license from OVM to develop the ROP technology in China.
In the new role Shisong will build on the existing research in the Department of Oncology to establish new links both within and outside of the University and will also take an active role in educating a new generation of scientists in industrial and translational medicine. His research group in the Department of Oncology, at the world leading medical school of the University of Oxford, will continue the development of new applications of the ROP technology including novel cancer vaccines, combinations with other immune oncology agents and the potential oral delivery of vaccines.
In a separate development, outside of the Department of Oncology, Shisong Jiang, has also been appointed an Associate Editor with the prestigious journal Frontiers of Immunology. This appointment recognizes the importance of his research and development of the ROP technology and Shisong’s extensive experience in immunology.
Shisong Jiang, Senior Industrial Fellow and CSO of Oxford Vacmedix said:
“I am very pleased to be appointed in this new role in the Department. The Department of Oncology at the University has a world class reputation for research and medicine, and I excited to have the opportunity now to be at the forefront of the Department’ new industrial strategy, to translate the benefits of our research to the clinic.”
Professor Mark Middleton, Head of the Department of Oncology at the University of Oxford, added:
“I am delighted to be able to support Dr. Shisong Jiang in his role of Senior Industrial Fellow in recognition of his exciting work in translational science. This role builds on the Department of Oncology’s portfolio of work with Industry, accelerating patient access to new treatments for cancer.”
For more information or to arrange an interview, please contact:
William Finch, CEO, Oxford Vacmedix
T: +44 (0)7769 903711 | E: firstname.lastname@example.org
Notes to Editor
About Oxford Vacmedix
Oxford Vacmedix UK Ltd, based on the Oxford Science Park, UK, is a bio-pharma company that utilizes the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Dr Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell immunity therefore forming a good platform for cancer therapeutic vaccines and diagnostics. The company is a spin-out of the University of Oxford and has extensive contacts and collaborations in China through Changzhou Bioscience that is using the ROP platform in both diagnostics and adoptive cell therapy.
For more information, please visit: https://www.oxfordvacmedix.com/
About the Department of Oncology, University of Oxford
The Department of Oncology’s mission is to improve cancer care through research and teaching. There is a strong emphasis on translation, with established infrastructure to develop scientific insight toward clinical applications. The Department houses over 250 staff and postgraduate students – both clinical and nonclinical – and is one of the key departments in the University of Oxford’s Medical Sciences Division. It is also home to the Institute for Radiation Oncology and houses the Structural Genomics Consortium. One of the key aims for the Department is to bring together basic scientific and clinical research groups across Oxford – based in the Old Road Campus Research Building, the Radiobiology Research Institute, the Weatherall Institute for Molecular Medicine and the NHS Cancer and Haematology Centre – to apply knowledge of cancer and to develop research to improve the understanding of how to combat cancer in the most effective way possible.
For more information, please visit: https://www.oncology.ox.ac.uk